The Moving Target: Cis-Mutation-Driven Resistance to p53-Y220C Reactivator - PubMed
10 hours ago
- #drug resistance
- #p53 mutation
- #clinical trial
- Study reveals secondary TP53 mutations drive resistance to p53-Y220C reactivator rezatapopt.
- Resistance observed in PYNNACLE clinical trial, where rezatapopt treatment selects for mutations on Y220C-mutant background.
- Secondary mutations abrogate therapeutic efficacy of rezatapopt.